[Diffuse @entity548 in XXXX ].

@entity1 @entity32 @entity417 @entity548 @entity55 @entity1252 @entity228 @entity3794 @entity1988 @entity364 @entity1576
Of the 120 @entity1252 ( @entity1252 ) @entity1 treated by the authors, two have developed @entity548 . The authors' objective is to present this rare, but severe manifestation. @entity1 1 and 2 were 66- and 22-year old @entity1 , respectively. Both had @entity1252 with multi-organ involvements including diffuse proliferative @entity1988 . Before the diagnosis of the disease, both @entity1 had experienced @entity55 that resolved on corticosteroid treatment. Soon after the diagnosis, @entity1576 , haemoptoea and acute @entity417 developed, accompanied by a rapid deterioration in the general condition. Chest radiographs revealed bilateral, diffuse, alveolar infiltrates. The @entity548 temporarily ceased in response to @entity228 treatment, but both @entity1 later died in consequence of active @entity1252 and mixed @entity364 . Post mortem examination demonstrated @entity3794 and @entity548 in @entity1 1, and an immune complex deposition-induced @entity32 with @entity548 in @entity1 2. @entity548 is a life-threatening manifestation of @entity1252 . Its onset may be preceded by episodes of @entity55 resolving on corticosteroid treatment. An active diagnostic workup, intensive observation and aggressive immunosuppressive treatment are the cornerstones of the management. The early detection and the active treatment of secondary infections are obligatory. The authors consider the most difficult challenge to be the optimum coordination of the above treatment modalities.
